Naloxegol

Drug Profile

Naloxegol

Alternative Names: AZ13337019 oxalate; Movantik; Moventig; Naloxegol oxalate; NKTR-118; NKTR-118 oxalate; Oral PEG-naloxol; Pegylated naloxol

Latest Information Update: 21 Dec 2016

Price : $50

At a glance

  • Originator Nektar Therapeutics
  • Developer AstraZeneca; Nektar Therapeutics
  • Class Morphinans; Small molecules
  • Mechanism of Action Opioid mu receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Constipation

Most Recent Events

  • 15 Dec 2016 Naloxegol licensed to Knight Therapeutics in Canada and Israel
  • 15 Dec 2016 Preregistration for Constipation in Israel (PO) before 15 December 2016
  • 18 Apr 2016 ProStrakan is now called Kyowa Kirin International
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top